Paradoxical oncogenesis: Are all BRAF inhibitors equal?

Alexander M. Menzies; Richard F. Kefford; Georgina V. Long

doi:10.1111/pcmr.12132

Paradoxical oncogenesis: Are all BRAF inhibitors equal?

Alexander M. Menzies^*, Richard F. Kefford, Georgina V. Long

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

44 Citations (Scopus)

Abstract

Summary: Cutaneous squamous cell carcinoma (cSCC) is a concerning toxicity with BRAF inhibitors in the treatment for melanoma. While the two drugs shown to improve survival, vemurafenib, and dabrafenib, have similar efficacy, the reported rates of cSCC are quite different. Drawing upon preclinical and clinical trial data, this article discusses the potential factors behind the different cSCC incidences reported with the two BRAF inhibitors and provides a strategic approach to understand this issue further.

Original language	English
Pages (from-to)	611-615
Number of pages	5
Journal	Pigment Cell and Melanoma Research
Volume	26
Issue number	5
DOIs	https://doi.org/10.1111/pcmr.12132
Publication status	Published - Sept 2013
Externally published	Yes

Access to Document

10.1111/pcmr.12132

Cite this

@article{354acc77533341c6b7a70202703dd677,

title = "Paradoxical oncogenesis: Are all BRAF inhibitors equal?",

abstract = "Summary: Cutaneous squamous cell carcinoma (cSCC) is a concerning toxicity with BRAF inhibitors in the treatment for melanoma. While the two drugs shown to improve survival, vemurafenib, and dabrafenib, have similar efficacy, the reported rates of cSCC are quite different. Drawing upon preclinical and clinical trial data, this article discusses the potential factors behind the different cSCC incidences reported with the two BRAF inhibitors and provides a strategic approach to understand this issue further.",

author = "Menzies, {Alexander M.} and Kefford, {Richard F.} and Long, {Georgina V.}",

year = "2013",

month = sep,

doi = "10.1111/pcmr.12132",

language = "English",

volume = "26",

pages = "611--615",

journal = "Pigment Cell and Melanoma Research",

issn = "1755-1471",

publisher = "Wiley-Blackwell, Wiley",

number = "5",

}

TY - JOUR

T1 - Paradoxical oncogenesis

T2 - Are all BRAF inhibitors equal?

AU - Menzies, Alexander M.

AU - Kefford, Richard F.

AU - Long, Georgina V.

PY - 2013/9

Y1 - 2013/9

N2 - Summary: Cutaneous squamous cell carcinoma (cSCC) is a concerning toxicity with BRAF inhibitors in the treatment for melanoma. While the two drugs shown to improve survival, vemurafenib, and dabrafenib, have similar efficacy, the reported rates of cSCC are quite different. Drawing upon preclinical and clinical trial data, this article discusses the potential factors behind the different cSCC incidences reported with the two BRAF inhibitors and provides a strategic approach to understand this issue further.

AB - Summary: Cutaneous squamous cell carcinoma (cSCC) is a concerning toxicity with BRAF inhibitors in the treatment for melanoma. While the two drugs shown to improve survival, vemurafenib, and dabrafenib, have similar efficacy, the reported rates of cSCC are quite different. Drawing upon preclinical and clinical trial data, this article discusses the potential factors behind the different cSCC incidences reported with the two BRAF inhibitors and provides a strategic approach to understand this issue further.

UR - http://www.scopus.com/inward/record.url?scp=84882919523&partnerID=8YFLogxK

U2 - 10.1111/pcmr.12132

DO - 10.1111/pcmr.12132

M3 - Article

C2 - 23795808

AN - SCOPUS:84882919523

SN - 1755-1471

VL - 26

SP - 611

EP - 615

JO - Pigment Cell and Melanoma Research

JF - Pigment Cell and Melanoma Research

IS - 5

ER -

Paradoxical oncogenesis: Are all BRAF inhibitors equal?

Abstract

Access to Document

Other files and links

Fingerprint

Cite this